|Bid||4.0500 x 2000|
|Ask||4.0700 x 900|
|Day's range||4.0000 - 4.1336|
|52-week range||3.2000 - 11.2000|
|PE ratio (TTM)||N/A|
|Earnings date||28 Mar 2018 - 2 Apr 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||65.00|
SAN FRANCISCO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology.
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. ...